Allozyne, PEGylated IFN beta

A board to discuss future MS therapies in early stage (Phase I or II) trials.

Allozyne, PEGylated IFN beta

Postby rainer » Thu Oct 16, 2008 9:32 pm

Allozyne, Developer of Multiple Sclerosis Drug in Fewer Shots, Poised to Enter Clinical Trials

Allozyne’s technology aims to enable what is known as “pegylation” of an interferon beta drug. That means scientists can attach a polymer that helps the drug remain stable for a longer period of time in the bloodstream to do its job. Instead of weekly injections, Allozyne thinks its candidate can be given every other week, or even once a month, Chhabra says. By avoiding the peaks and valleys in bloodstream concentration between injections, the drug might offer improved effectiveness at reducing brain lesions in MS patients, Chhabra says.

User avatar
Family Elder
Posts: 367
Joined: Thu Jan 17, 2008 4:00 pm


Return to Drug Pipeline


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service